Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11551239 | 0.84 | RAB9A (0.62) | ASIC3CYP2D6RAB9AARNPC1 | |
| SCHEMBL30465795 | 0.82 | ASIC3 (1.00) | ASIC3RAB9ANPC1CYP3A4PDPK1 | |
| SCHEMBL1039866 | 0.82 | ASIC3 (1.00) | ASIC3RAB9ANPC1CYP3A4PDPK1 | |
| SCHEMBL18745706 | 0.81 | KMT2A (0.48) | ASIC3CYP2D6RAB9AARNPC1 | |
| SCHEMBL12443810 | 0.80 | ASIC3 (0.72) | ASIC3RAB9ANPC1CYP3A4PDPK1 | |
| SCHEMBL9275978 | 0.78 | ASIC3 (0.91) | ASIC3RAB9ANPC1CYP3A4PDPK1 | |
| SCHEMBL29601960 | 0.78 | ASIC3 (0.68) | ASIC3CYP2D6RAB9ANPC1CYP1A2 | |
| SCHEMBL1073895 | 0.78 | ASIC3 (0.68) | ASIC3CYP2D6RAB9ANPC1CYP1A2 | |
| SCHEMBL901899 | 0.78 | ASIC3 (0.57) | ASIC3PDPK1KMT2AMEN1NOS3 | |
| SCHEMBL210834 | 0.78 | CYP2A6 (0.62) | ASIC3CYP2D6RAB9ANPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663283-B1 | CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THIN FILM FORMED FROM THE COMPOSITION | SAMSUNG DISPLAY CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| EP-3428149-B1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2021-07-28 | — | — | EP | disclosed |
| EP-3301097-B1 | [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | SAMSUNG DISPLAY CO LTD (KR) | 2020-08-19 | — | — | EP | disclosed |
| EP-3693372-A1 | BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | Samsung Display Co., Ltd. (KR) | 2020-08-12 | — | — | EP | disclosed |
| CN-107406425-B | As adenosine A2bReceptor antagonists and melatonin MT32-aminopyridine derivatives of ligands for receptors | 帕罗生物制药有限公司 | 2020-06-26 | — | — | CN | disclosed |
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | PALOBIOFARMA, S.L. (ES) | 2019-04-09 | — | — | US | disclosed |
| EP-3339395-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2018-06-27 | — | — | EP | disclosed |
| EP-2980182-B1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-05-23 | — | — | EP | disclosed |
| EP-3301097-A2 | [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | Samsung Display Co., Ltd. (KR) | 2018-04-04 | — | — | EP | disclosed |
| US-20180037569-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | PALOBIOFARMA, S.L. (ES) | 2018-02-08 | — | — | US | disclosed |
| WO-2014081166-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 주식회사 두산 (KR) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014025114-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 주식회사 두산 (KR) | 2014-02-13 | — | — | WO | disclosed |
| EP-2668162-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101063-A1 | N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101062-A1 | SUBSTITUTED BI-HETEROARYL COMPOUNDS AS CDK9 INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| EP-2441755-A1 | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors | Almirall, S.A. (ES) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012041476-A1 | PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-05 | — | — | WO | disclosed |
| US-6211220-B1 | ANTITUMOR AGENTS AND ANTICARCIINOGENIC AGENTS | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1994029277-A1 | AMILINO- OR PYRIDYLAMINO- CYCLOBUTENE- 1,2-DIONE DERIVATIVES AS cGMP PHOSPHODIESTERASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253017-B2 | Derivatives of 2-aminopyridine as adenosine A2B receptor antagonists and ligands of the melatonin MT3 receptors | ADORA2B, MTNR1A, ADORA3 | ASIC3 500/4885CYP2D6 656/4885RAB9A 2185/4885 |
| US-20180037569-A1 | DERIVATIVES OF 2-AMINOPYRIDINE AS ADENOSINE A2B RECEPTOR ANTAGONISTS AND LIGANDS OF THE MELATONIN MT3 RECEPTORS | ADORA2B, MTNR1A, ADORA3 | ASIC3 500/4885CYP2D6 656/4885RAB9A 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.